Renal denervation - Current evidence and perspectives

Postepy w Kardiologii Interwencyjnej

Volumn 9, Issue 4, 2013, Pages 362-368

  Warchoł Celińska, Ewa ^a   Prejbisz, Aleksander ^a   Florczak, Elzbieta ^a   Kaḑziela, Jacek ^a   Witkowski, Adam ^a   Januszewicz, Andrzej ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Hypertension; Renal denervation; Resistant hypertension

Indexed keywords

ADRENERGIC SYSTEM; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FAILURE; PATIENT SAFETY; PATIENT SELECTION; RESISTANT HYPERTENSION; REVIEW; SLEEP DISORDERED BREATHING; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION;

EID: 84890913325     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2013.38866     Document Type: Review

References (38)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
2. Fagard RH. Resistant hypertension. Heart 2012; 98: 254-261.
3. Dela Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classifiedon the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 171-174.
4. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-1080.
6. Florczak E, Prejbisz A, Szwench-Pietrasz E, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens 2013; 27: 678-685.
7. Szwench E, Florczak E, Prejbisz A, Resistant hypertension - progress in diagnosis ans treatment. Kardiol Pol 2012; 70: 66-74.
8. Mahfoud F, Luscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34: 2149-2157.
9. Witkowski A, Januszewicz A, Imiela J, et al. Stanowisko grupy ekspertów w sprawie zabiegów przez skórnej denerwacji nerek w leczeniu nadciśnienia tȩtniczego w Polsce [Polish]. Kardiol Pol 2011; 69: 1208-1211.
10. Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841.
11. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 2009; 54: 690-697.
12. Sobotka PA, Mahfoud F, Schlaich MP, et al. Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011; 100: 1049-1057.
13. Kirchheim H, Ehmke H, Persson P. Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989; 67: 858-864.
14. Kon V. Neural control of renal circulation. Miner Electrolyte Metab 1989; 15: 33-43.
15. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension: review of 122 cases. Lancet 1953; 1: 403-408.
16. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
17. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
18. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917.
19. Krum H, Schlaich M, Sobotka PA, et al. TCT-12 long-termfollow-up of catheter-based renal denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol 2012; 60: doi: 10.1016/j.jacc.2012. 08.017.
20. Petidis K, Anyfanti P, Doumas M. Renal sympathetic denervation: renal function concerns. Hypertension 2011; 58: e19.
21. Mahfoud F, Ukena C, Roland E, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013; 128: 132-140.
22. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528-535.
23. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-424.
24. Hering D, MahfoudF,Walton AS, et al. Renal denervation in moderate tosevere CKD. J Am Soc Nephrol 2012; 23: 1250-1257.
25. Ukena C, Mahfoud F, Kindermann I. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2011; 58: 1176-1182.
26. Mahfoud F, Lenski M, Ukena C, et al. Influence of renal sympathetic denervation on orthostatic function in patients with resistant hypertension. Circulation 2012; 126: A17201.
27. Masuo K, Mikami H, Ogihara T, et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 1997; 10: 77-83.
28. Grassi G, Dell'Oro R, Facchini A, et al. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363-2369.
29. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003; 108: 3097-3101.
30. Grassi G, Dell'Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-1365.
31. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946.
32. Schlaich MP, Straznicky N, Grima M. Renal denervation: a potential new treatment modality forpolycystic ovary syndrome? J Hypertens 2011; 29: 991-996.
33. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565.
34. Brandt MC, Mahfoud F, Reda S. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-909.
35. Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH Pilot study. Int J Cardiol 2013; 162: 189-192.
36. Verloop WL, Beeftink MM, Nap A, et al. Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmalLv Ejection fraction) trial. Eur J Heart Fail 2013 Sep 16 [Epub ahead of print].
37. Ukena C, Bauer A, Mahfoud F, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol 2012; 101: 63-67.
38. Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60: 1163-1170.